This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A New Multi-parameter Neuromonitoring System to Save Patients' Lives in Stroke and Brain Injury

This study has been completed.
Sponsor:
Collaborators:
Medical University of Graz
University of Zurich
Information provided by (Responsible Party):
NeMoDevices AG
ClinicalTrials.gov Identifier:
NCT01802762
First received: February 24, 2013
Last updated: September 4, 2017
Last verified: September 2017
  Purpose
To assess the feasibility of a new neuromonitoring system (NeMoSystem including NeMo Probe and NeMo Patch) and the accuracy of the measurement values (cerebral blood flow (CBF); cerebral blood volume (CBV)) obtained.

Condition Intervention
Subarachnoid Hemorrhage Optical Imaging Device: NeMo Patch and NeMo Probe

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A New Multi-parameter Neuromonitoring System to Save Patients' Lives in Stroke and Brain Injury

Further study details as provided by NeMoDevices AG:

Primary Outcome Measures:
  • To assess the feasibility of the neuromonitoring system and the accuracy of the measurement values. [ Time Frame: Day 28 after removal of medical device ]

    Feasibility:

    User acceptance: For NeMo Probes in comparison to conventional probes for intracranial pressure (ICP-) monitoring; for NeMo Patch in comparison to patches for electroencephalography (EEG) monitoring.

    Detailled evaluation of user acceptance:

    • Incidence of concerns of users in relation to the installation, function and removal of the NeMo System (= NeMo Probe, NeMo Patch, NeMo Control Unit and NeMo Software pre-installed on a Medical PC)
    • User-friendliness with a 3-graded scale (equal, better, worse) compared to conventional devices

    Accuracy of measurements:

    -Patients: Results from repeated measurements of mean transit time of ICG (mttICG), cerebral blood flow (CBF) and cerebral blood volume (CBV)

    Safety parameters:

    Incidence of complications (infections, brain tissue damage, haemorrhage) compared to historical series (patches for EEG and for BIS measurements; conventional probes for ICP monitoring)



Secondary Outcome Measures:
  • To demonstrate the ability of the neuromonitoring system to detect secondary ischemic events in patients with severe subarachnoid haemorrhage (SAH) or severe traumatic brain injury (TBI). [ Time Frame: Day 28 after removal of medical device ]
    Results concerning sensitivity and specificity to detect symptomatic vasospasm in patients with subarachnoid hemorrhage (SAH) (correlation of events with CBF values < 15 ml/100g/min with defined criteria for vasospasm) Results concerning sensitivity and specificity to detect secondary infarctions and critical ICP values in TBI patients (correlation of events with CBF values < 15 ml/100g/min with defined criteria for secondary infarction) Results from repeated measurements for the difference between measurement values obtained with the NeMo Patch and the NeMo Probe, quantified with mathematical models


Enrollment: 16
Actual Study Start Date: January 2013
Study Completion Date: May 2017
Primary Completion Date: February 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
NeMo Patch and NeMo Probe
TBI and SAH patients, one arm
Device: NeMo Patch and NeMo Probe
A plaster based patch (NeMo Patch) and a combined probe for ICP monitoring and near infrared spectroscopy (NIRS) are applied as sensors. Data are collected by a NIRS instrument (NeMo Control Unit)

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Adult male or female patient, ≥ 18 and ≤ 75 years
  2. Patient with severe SAH (GCS ≤ 12) or severe TBI (GCS ≤ 8)
  3. Decreased level of consciousness with the need for ICP monitoring for an estimated duration of more than 3 days
  4. Negative pre-treatment serum pregnancy test for female patients with childbearing potential
  5. In patients with severe SAH or severe TBI with need for ICP monitoring an acute emergency situation exists. The inclusion follows

Exclusion Criteria:

  1. Known kidney disease, defined as plasma creatinine > 120 µmol/l
  2. Known liver disease, defined as GOT > 200U/l
  3. History of allergic disorders, including allergic reactions against contrast agents containing iodine, against ICG and against plasters, as well as patients with thyroid disease causing hyperthyroidism
  4. Pre-existing disability and/or legal representative
  5. Participation in another interventional clinical trial within the last 30 days before start of treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01802762

Locations
Austria
Dept. of Neurosurgery, Medical University of Graz
Graz, Austria, 8036
Switzerland
Neurointensive Care Unit, University Hospital Zurich
Zurich, Switzerland, 8091
Sponsors and Collaborators
NeMoDevices AG
Medical University of Graz
University of Zurich
  More Information

Additional Information:
Responsible Party: NeMoDevices AG
ClinicalTrials.gov Identifier: NCT01802762     History of Changes
Other Study ID Numbers: P-1.000_NeMo_C001 / MUG
E!6526_OPTO-BRAIN ( Other Grant/Funding Number: European Union )
Study First Received: February 24, 2013
Last Updated: September 4, 2017

Additional relevant MeSH terms:
Brain Injuries
Hemorrhage
Subarachnoid Hemorrhage
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System
Wounds and Injuries
Pathologic Processes
Intracranial Hemorrhages
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on September 21, 2017